Khusinol is a sesquiterpene alcohol reported from vetiver oil and occasionally highlighted as a marker in specific chemotypes and root-oil datasets. Compared with khusimol or the vetivones, the direct public evidence base is much thinner and more fragmented across identity notes, occurrence tables, and a small number of newer bioactivity leads. For AromaForge, this record should stay explicitly evidence-limited: useful for vetiver chemistry, odor-context, and a few early mechanistic signals, but not for strong standalone health claims.
Chemical identity and composition
NIST indexes khusinol under CAS 24268-34-6 with formula C15H24O, and Good Scents maps the same CAS to the name khusinol with isolongifolan-7-alpha-ol as a synonym string. Public database coverage is less tidy than for khusimol or khusimone, so this record keeps the alias mapping conservative. Local archive occurrence is currently explicit in Papuan red vetiver material at 1.2%.
Aroma and practical use
- Use the recorded woody, earthy, rooty, vetiver-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 1963 structure paper described khusinol as a new crystalline secondary sesquiterpene alcohol isolated from North Indian vetiver oil and assigned its absolute-structure framework.
A 1963 structure paper described khusinol as a new crystalline secondary sesquiterpene alcohol isolated from North Indian vetiver oil and assigned its absolute-structure framework.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2025 snippet-level article reported concentration-dependent vasorelaxation of crystalline khusinol in rat superior mesenteric artery and also noted moderate anti-neuroinflammatory effects in BV2 cells.
A 2025 snippet-level article reported concentration-dependent vasorelaxation of crystalline khusinol in rat superior mesenteric artery and also noted moderate anti-neuroinflammatory effects in BV2 cells.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A PubMed-indexed 2015 aroma-composition paper on turmeric rhizome oil identified khusinol as the major constituent at 36.2%, which is useful as occurrence evidence even though it is outside vetiver and not a pharmacology paper.
A PubMed-indexed 2015 aroma-composition paper on turmeric rhizome oil identified khusinol as the major constituent at 36.2%, which is useful as occurrence evidence even though it is outside vetiver and not a pharmacology paper.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific human safety, dermal limit, reproductive toxicology, or inhalation study for isolated khusinol was verified in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The Good Scents entry reviewed for this pass did not provide a usable positive fragrance or flavor-use recommendation and instead reflected very limited public safety-use detail.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
vasorelaxation signal
A 2025 snippet-level study describes concentration-dependent vasorelaxation for crystalline khusinol in rat superior mesenteric artery preparations, suggesting an early ex vivo vascular activity signal.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
moderate anti neuroinflammatory signal
The same 2025 report also mentions moderate anti-neuroinflammatory effects against BV2 cells and docking-based interaction analysis, but the accessible evidence is still limited to preclinical and snippet-level reporting.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Identity and synonym handling for khusinol are less standardized across public databases than for the other two assigned constituents.
- Constituent-specific safety literature for isolated khusinol was not verified in this pass.
- The main accessible bioactivity signal is recent, preclinical, and snippet-level, so mechanism and efficacy language should stay cautious.
- Targeted web search for an IFRA/Tisserand/EU Annex III dermal limit and sensitization/phototoxicity data specific to khusinol (CAS 24268-34-6) returned no authoritative results (2026-07-13). The previously stored dermal_limit_pct (20) and sensitizing:true had no supporting citation and have been corrected to null/unknown pending real data.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.